Skip to main content

Table 1 Study eligibility criteria defined according to PICOS

From: Establishing core outcome sets for phenylketonuria (PKU) and medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency in children: study protocol for systematic reviews and Delphi surveys

PICOS component

PKU and MCAD deficiency

Other COMET paediatric projects

Population

(i) Children (aged 18 years or younger) diagnosed with PKU or MCAD deficiency

Children (aged 18 years or younger) diagnosed with a paediatric condition

(ii) For publications focused on long-term follow-up initiatives for newborn screening programmes, children (aged 18 years or younger) diagnosed with inherited metabolic diseases generally (including but not limited to PKU and MCAD deficiency)

Exclusions: for (ii) above, publications describing long-term follow-up initiatives for newborn screening, we will exclude publications where neither PKU nor MCAD deficiency are encompassed within the set of diseases being studied

 

Interventions/comparators/exposures

As the review’s objectives are to establish a listing of reported outcomes, no restrictions will be in place related to specific interventions or exposures

Outcomes

No restrictions will be in place in terms of outcomes, given the objectives of the review; mapping of reported outcomes will be established

Study design

(i) Eligibility will be restricted to non-animal studies of PKU and MCAD deficiency, using any study design

Eligibility will be restricted to publications describing findings from core outcome initiatives related to otherpaediatric conditions (nonspecific to PKU or MCAD)

(ii) Publications focused on long-term follow-up initiatives related to newborn screening and IMD (which include PKU and/or MCAD deficiency within a larger group of diseases)

Exclusions: case reports and case series with fewer than 5 subjects

Language

English

English

  1. PICOS patient, population or problem, intervention, comparison, outcomes and study design/setting, PKU phenylketonuria, MCAD medium-chain acyl-CoA dehydrogenase, COMET Core Outcome Measures in Effectiveness Trials, IMD inherited metabolic diseases